Responses
Immune cell therapies and immune cell engineering
Original research
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
Compose a Response to This Article
Other responses
No responses have been published for this article.
